Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

News | PET Imaging

Molecular Targeting Technologies, Inc. Announces New PET Imaging Agent

April 19, 2021 — Molecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953 ...

April 19, 2021

The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging

Promising Results from First-in-humans Study of a Novel PET Radiopharmaceutical

April 19, 2021 — The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed ...

April 19, 2021

#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress

April 16, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

April 16, 2021

Sponsored Content

Videos | Proton Therapy

HYPERSCAN: Pencil Beam Scanning Delivered at Hyper Speed

Introducing HYPERSCAN , Pencil Beam Scanning Delivery HYPERSCAN enables tumor volumes to be scanned in a matter of ...

October 06, 2014

Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph Vision Quadra, a positron emission tomography/computed tomography (PET/CT) scanner designed for clinical use as well as translational research – or the application of scientific research to create therapies and procedures that improve health outcomes. In this manner, the Biograph Vision Quadra expands precision medicine.

News | PET-CT

Siemens Healthineers Announces FDA Clearance of Biograph Vision Quadra Extended Axial FoV PET/CT Scanner

March 8, 2021 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph ...

March 08, 2021

Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.

Feature | Treatment Planning | By Melinda Taschetta-Millane

Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and ...

March 05, 2021

CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019.

Feature | Radiation Dose Management | By Dave Fornell

Medical Imaging Radiation Exposure in U.S. Dropped Over Past Decade

More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that was ...

March 04, 2021

Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer

News | PET-CT

Model Helps Predict Which Patients will Benefit Most from PSMA PET Scan

February 23, 2021 — A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which ...

February 23, 2021

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging

Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment

February 22, 2021 — Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2 ...

February 22, 2021

After acquiring the molecular breast imaging (MBI) assets from GE Healthcare and Dilon Technologies, Inc., SmartBreast Corporation (SmartBreast), a privately held company focused on breast cancer screening and diagnosis, announced today that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture molecular breast imaging (MBI) systems.

News | Breast Imaging

SmartBreast Forms Molecular Breast Imaging Partnership with FITI

February 9, 2021 — After acquiring the molecular breast imaging (MBI) assets from GE Healthcare and Dilon Technologies ...

February 09, 2021

Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti

News | PET Imaging

Imaging Identifies Breast Cancer Patients Unlikely to Benefit from Hormone Therapy

February 3, 2021 — Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry ...

February 03, 2021

NMP to evaluate technology to create new class of PET radiopharmaceuticals

News | PET Imaging

Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility ...

January 29, 2021

Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging

News | PET Imaging

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

January 18, 2021

Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep

News | PET Imaging

Imaging the Twilight Zone

December 30, 2020 — What happens in the brain when our conscious awareness fades during general anesthesia and normal ...

December 30, 2020

A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.

News | Nuclear Imaging

New Diagnostic Isotope to Enhance Targeted Alpha Therapy for Cancer

December 22, 2020 — Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a ...

December 22, 2020